Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study

<p>Abstract</p> <p>Background</p> <p>Based on a large, representative unscreened cohort from Malmö, Sweden, we have recently reported that a single prostate-specific antigen (PSA) measurement at or before age 50 is a strong predictor of prostate cancer occurring up to 2...

Full description

Bibliographic Details
Main Authors:	Berglund Göran, Vickers Andrew J, Becker Charlotte, Eastham James A, Scardino Peter T, O'Brien Matthew F, Björk Thomas, Cronin Angel M, Ulmert David, Lilja Hans
Format:	Article
Language:	English
Published:	BMC 2008-02-01
Series:	BMC Medicine
Online Access:	http://www.biomedcentral.com/1741-7015/6/6

Similar Items

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study.
by: Ulmert, D, et al.
Published: (2008)

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.
by: Lilja, H, et al.
Published: (2011)

Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
by: Ulmert, D, et al.
Published: (2008)

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
by: Lilja, H, et al.
Published: (2007)

The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy.
by: Vickers, A, et al.
Published: (2007)

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: Case-control study
by: Vickers, A, et al.
Published: (2010)

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.
by: Vickers, A, et al.
Published: (2010)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
by: Lilja, H, et al.
Published: (2008)

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.
by: Savage, C, et al.
Published: (2010)

Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring (Corrigendum) (Nature Reviews Cancer (2008) 8, (268-278))
by: Lilja, H, et al.
Published: (2008)

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.
by: Vickers, A, et al.
Published: (2010)

Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively.
by: O'Brien, M, et al.
Published: (2011)

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.
by: Vickers, A, et al.
Published: (2009)

Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C.
by: Ulmert, D, et al.
Published: (2006)

Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
by: O'Brien, M, et al.
Published: (2009)

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
by: Vickers, A, et al.
Published: (2010)

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
by: Vickers, A, et al.
Published: (2009)

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
by: Steuber, T, et al.
Published: (2007)

Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.
by: Wenske, S, et al.
Published: (2009)

Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.
by: Klein, R, et al.
Published: (2012)

Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
by: Christensson, A, et al.
Published: (2011)

Addition of Prostate Volume and Prostate-specific Antigen Density to Memorial Sloan Kettering Cancer Center Prostate Cancer Nomograms
by: Michael Tzeng, et al.
Published: (2021-08-01)

Prostate kallikrein markers in diagnosis, risk stratification and prognosis.
by: Ulmert, D, et al.
Published: (2009)

Five genetic variants associated with prostate cancer.
by: Vickers, A, et al.
Published: (2008)

Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.
by: Carlsson, S, et al.
Published: (2012)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
by: Scardino Peter T, et al.
Published: (2008-07-01)

Predicting prostate cancer many years before diagnosis: how and why?
by: Vickers, A, et al.
Published: (2012)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden.
by: Vickers, A, et al.
Published: (2008)

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
by: Vickers, A, et al.
Published: (2011)

Prostatic specific antigen for prostate cancer detection
by: Lucas Nogueira, et al.
Published: (2009-10-01)

Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.
by: Ulmert, D, et al.
Published: (2012)

Prostate cancer polygenic risk score and prediction of lethal prostate cancer
by: Robert J. Klein, et al.
Published: (2022-04-01)

Screening for prostate cancer: an update.
by: Shariat, S, et al.
Published: (2008)

Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
by: Steuber, T, et al.
Published: (2006)

Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment.
by: Bruun, L, et al.
Published: (2003)

Biology of prostate-specific antigen
by: Lilja, H
Published: (2003)

Biology of prostate-specific antigen.
by: Lilja, H
Published: (2003)

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
by: Vickers, A, et al.
Published: (2010)

Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
by: Steuber, T, et al.
Published: (2007)

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
by: Vickers, A, et al.
Published: (2010)